The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering Raf inhibitors in combination with Aurora kinase inhibitors. The present disclosure relates to methods of treating subject suffering from cancer, comprising administering to the subject a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof； and an Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof； the amount of said Raf kinase inhibitor or a pharmaceuticall acceptable salt thereof being such that the combination thereof is therapeutically effective in the treatment of the cancer. In some [embodiments, the cancer is a solid tumor cancer.
